04.29.25 -- Biotech Hiring Heats Up; Advances In Cell & Gene Therapy

We know how tough it can be to find the right CDMO, especially when capacity is tight and timelines are critical. That's why you’ll find our collection of recent Outsourced Pharma Capacity Update presentations so valuable. Our April Partners Week Update details the latest capabilities and available capacity from 40 leading CDMOs – and you can experience it all from the convenience of your screen. View the on-demand sessions for the modalities that fit your needs.

Induced pluripotent stem cells offer some key biologic, technical, and financial advantages over more established PBMC-derived therapies.

Conduct a smooth and efficient technology transfer by following key strategies and avoiding common pitfalls to streamline your process and achieve consistent, error-free results.

Learn about the rapid growth occurring in the gene and cell therapy industry, driven by technological advancements, an increasing number of development programs, and recent product approvals.

The manufacturing process for autologous therapies is complex and highly customized, requiring well-orchestrated transport, careful planning, and tight control of many discrete and manual processing steps.

When it comes to furthering AAV's potential in the wider biopharmaceutical pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

Optimize your mRNA production with an advanced IVT process, enhancing scalability, purity, and expression activity for clinically relevant RNA therapeutics.

Consider our novel ddPCR method for assessing plasmid-derived antibiotic resistance gene impurities in rAAV products to ensure regulatory compliance, safety, and quality of gene therapy vectors.

Ensure the seamless development and commercialization of your ATMPs in Europe with integrated supply chain solutions that optimize logistics, biostorage, and regulatory compliance.

Discover how our innovative rAAV production platform can revolutionize your gene therapy pipeline with unparalleled yield, quality, and scalability.

What is actually behind the procurement of a pharmaceutical labeling machine and how does the process work? You can find out here what the path to your pharmaceutical labeling machine looks like.

Discover how CDMOs can help you achieve and maintain CMC compliance throughout the drug development lifecycle. Outsourced Pharma Live will explore how to leverage CDMO expertise in process optimization, documentation, and regulatory submissions. Learn practical strategies to align your CMC goals with CDMO capabilities to accelerate development and ensure successful drug launches. Registration is free thanks to the support of Curia.

Here, we present new capacity and capabilities of our complete mRNA Ecosystem, offering streamlined services for process development, manufacture, and release of both mRNA drug substance and product.

Our 360˚ approach covers everything from discovery to delivery, including research, process development, manufacturing, commercialization, cold chain supply, and more.

Operating through a global network of cGMP-certified facilities strategically located across key regions, we ensure the highest standards of quality, safety, and compliance.

Leveraging the technology, expertise, and capacity of a cell therapy CDMO is crucial to reduce timelines and lower costs as you bring your novel cell therapy from discovery to commercialization.